Puma Biotechnology Inc (PBYI) Social Stream
PUMA BIOTECHNOLOGY INC (PBYI) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering PBYI.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-04 | 6 | $15 | $5 | $8.6 | $4.39 | 95.9% |
| 2022-03-07 | 6 | $15 | $5 | $8.4 | $4.39 | 91.34% |
| 2022-05-09 | 6 | $14 | $5 | $8.2 | $4.39 | 86.79% |
| 2022-05-19 | 5 | $12 | $4 | $7.6 | $4.39 | 73.12% |
| 2022-08-05 | 5 | $11 | $4 | $6.8 | $4.39 | 54.9% |
| 2022-08-08 | 5 | $11 | $4 | $7 | $4.39 | 59.45% |
| 2022-09-17 | 4 | $11 | $4 | $7 | $4.39 | 59.45% |
| 2023-11-03 | 3 | $8 | $4 | $5.666 | $4.39 | 29.07% |
| 2023-11-06 | 3 | $8 | $4 | $5.333 | $4.39 | 21.48% |
The Trend in the Analyst Price Target
Over the past 42 months, PBYI's average price target has gone down $7.17.
PBYI reports an average of 70.2% for its upside potential over the past 40 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-27 | 3 | 8 | 4 | 5.666 | 4.24 | 33.63% |
| 2023-03-03 | 3 | 8 | 4 | 5.666 | 3.21 | 76.51% |
| 2023-08-04 | 3 | 8 | 4 | 5.666 | 3.82 | 48.32% |
| 2023-11-03 | 3 | 8 | 4 | 5.666 | 2.78 | 103.81% |
| 2023-11-06 | 3 | 8 | 4 | 5.333 | 2.81 | 89.79% |
PBYI Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.67 | 1 | 0 | 1 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
PBYI's average broker recommendation rating improved by 0 over the prior 35 weeks.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for PBYI as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, PUMA BIOTECHNOLOGY INC's average analyst price target is higher than 67.95% of them.
- To contextualize these metrics, consider that out of all US stocks, PUMA BIOTECHNOLOGY INC's variance in analysts' estimates is lower than -762.74% of them.
- PBYI has a greater number of analysts covering the stock than 194.67% of stocks in the mid market cap category.
- PBYI has a higher upside potential (average analyst target price relative to current price) than 657.85% of stocks in the mid market cap category.
In the Pharmaceutical Products industry, ENTA, MDGL, and MGNX are the three stocks most similar to PUMA BIOTECHNOLOGY INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding PBYI using the data that counts. Try POWR Ratings for free.